Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GLP-1 Metabolic

Retatrutide vs Semaglutide

Retatrutide and Semaglutide represent two GLP-1-class generations. Semaglutide is the established, FDA-approved GLP-1 receptor agonist with large clinical datasets. Retatrutide is a Phase 2 triple agonist (GLP-1, GIP, glucagon) with dramatic preliminary weight-loss data but no registration yet.

Bangkok research desk ·

Side-by-side

Retatrutide Semaglutide
MechanismGLP-1 receptor agonist.Triple agonist: GLP-1, GIP, and glucagon.
Half-life~7 days.Extended (weekly dosing).
Dose0.25-2.4 mg weekly SC.0.5-12 mg weekly SC (research phase).
Cycle16-week titration, then maintenance.Research phase; less standardised.
Research contextSTEP, SUSTAIN, SELECT trials; FDA-approved1.Phase 2 obesity trial showed dose-dependent weight loss2; unestablished long-term safety.
Cost tierMid-to-high.High (research-grade scarcity).

Retatrutide and Semaglutide sit at different points on the evidence-strength curve. Semaglutide has a deep clinical dataset: STEP-1 for obesity weight loss, SUSTAIN-6 for cardiovascular outcomes in T2DM, SELECT for cardiovascular outcomes in obesity without diabetes1. The drug is approved, widely available, and has a well-characterised safety profile.

Retatrutide has a dramatic Phase 2 weight-loss signal but the evidence base is still early2. The Phase 2 obesity trial showed dose-dependent weight reductions at 48 weeks that exceeded comparable trial arms of other GLP-1 agonists. The mechanism is a triple agonist at GLP-1, GIP, and glucagon receptors; the glucagon component drives additional energy expenditure, which is the proposed explanation for the magnitude of the weight loss. But long-term safety, cardiovascular outcomes, and head-to-head trials have not completed.

Research-protocol selection typically depends on the question. A researcher with a hard endpoint that needs comparator-grade clinical data selects Semaglutide. A researcher studying the triple-agonist pharmacology itself, or running exploratory weight-loss protocols with appropriate safety monitoring, selects Retatrutide. Head-to-head clinical trials are pending; existing comparisons are cross-trial indirect. See the GLP-1 research overview for the full class context and GLP-1 titration protocols for dose schedules.

Frequently asked

Is Retatrutide better than Semaglutide for weight loss?
Retatrutide's Phase 2 trial showed greater mean weight reductions at the 12 mg dose than comparable trial arms of Semaglutide, but the comparison is indirect and Retatrutide is still research-phase2. No head-to-head trial has completed.
Is Retatrutide safe?
Short-term Phase 2 tolerability was comparable to other incretin agonists (dose-dependent GI effects). Long-term safety, cardiovascular outcomes, and rare adverse events are not yet characterised. Research use should account for this.
Why does Retatrutide have a triple-agonist mechanism?
The GLP-1 and GIP components drive satiety and insulin-sensitivity effects similar to Tirzepatide. The glucagon component adds an energy-expenditure pathway that appears responsible for the greater weight-loss magnitude.
Research desk
Ordering both Retatrutide and Semaglutide for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021. PMID: 33567185
  2. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315

All references verified against PubMed via NCBI E-utilities.